With over 25 years of executive leadership experience, Patrick NJ Schnegelsberg brings a wealth of experience and a proven track record in the medical device sector to SynCardia. Patrick has served as CEO of Syntach AB, and as COO and CEO with the Occlutech Group and its subsidiaries. He also held C-level positions with European and U.S. med- and biotech start-ups, including a U.S.-listed biotech company. Before working with industry, Patrick held Director-level positions with buy- and sell-side firms on Wall Street, including MP Asset Managers, and Rodman& Renshaw, and he worked as management consultant with Booz&Co. Patrick has conducted extensive research in molecular biology at MIT and graduated from Harvard Medical School. He currently serves on the board of Acorai AB and is a former board member of Scandinavian Real Heart.